Eli Lilly has solidified its lead in the obesity drug market following Novo Nordisk's disappointing trial results for CagriSema, which failed to match Lilly's Zepbound in efficacy. Data indicated that CagriSema users lost only 20.2% of body weight compared to Zepbound's 25.5%, resulting in a significant 16.4% drop in Novo's stock. Concurrently, Eli Lilly shares rose nearly 4%, reflecting strong investor confidence bolstered by robust growth in their GLP-1 weight-loss portfolio.
“New Chief Executive Officer Mike Doustdar has pledged aggressive action, including deals, as Novo looks for successors to blockbusters Wegovy and Ozempic and seeks to close the growing gap with Lilly.”
“specifically, whereas patients receiving subcutaneous injections of Lilly's tirzepatide lost an average of 25.5% of their body weight over 84 weeks, CagriSema users only lost an average of 23%.”
“Novo Nordisk shares fell sharply after the Danish drugmaker said an experimental obesity treatment failed to beat the weight loss delivered by Eli Lilly’s Zepbound.”
“The company has focused much more on oral peptides and less on small molecules compared to competitor Eli Lilly.”
“Novo Nordisk says weight loss drug fails to match Eli Lilly's in trial, @annikakimc reports.”
“Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly. https://t.co/wMu1o2Ztxw”
“Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study.”
“Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan.”
“Eli Lilly announced on @GMA that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month of treatment in one device.”
“Novo Nordisk shares fell, wiping away the last gains Wegovy's launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in a trial.”
“Novo Nordisk's stock has lost more than half its value over the past year, as Wegovy loses market share to Eli Lilly’s product in the U.S. and competes with compounded medicines.”
“Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide.”
.jpg&width=160)
